Table 1 Demographics and comorbidities of study participants
Post-COVID- Condition (PCC; n = 89) | Unimpaired Post-COVID (UPC; n = 38) | Healthy Controls (HC; n = 46) | ||
|---|---|---|---|---|
Demographic data | n (%) or median [IQR]; range | (%) or median [IQR]; range | (%) or median [IQR]; range | P value |
Age (years) | 49 [23]; 19 to 72 | 42 [24]; 25 to 62 | 44 [31]; 21 to 80 | 0.2192a |
Sex (male/female) | 34 (38)/55 (62) | 13 (34)/25 (66) | 23 (50)/23 (50) | 0.281b |
Δ positive PCR - cMRI (days) | 254 [209]; 90 to 710 | 227 [292]; 145 to 943 | NA | 0.626a |
Comorbidities | n (%) | n (%) | n (%) | P valuec |
Achalasia | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
Adipositas | 12 (14%) | 3 (8%) | 0 (0%) | 0.017 |
Arterial hypertension | 19 (21%) | 4 (10%) | 0 (0%) | <0.001 |
Asthma/COPD | 8 (9%) | 1 (3%) | 1 (2%) | 0.238 |
Atrial fibrillation | 1 (1%) | 0 (0%) | 0 (0%) | 0.999 |
Chronic kidney failure | 1 (1%) | 0 (0%) | 0 (0%) | 0.999 |
Coronary heart disease | 3 (3%) | 1 (3%) | 1 (2%) | 0.999 |
Deep vein thrombosis | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
Diabetes | 5 (6%) | 1 (3%) | 0 (0%) | 0.256 |
Gout | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
History of depression | 9 (10%) | 2 (5%) | 0 (0%) | 0.06 |
History of ischemic stroke | 2 (2%) | 0 (0%) | 0 (0%) | 0.725 |
Fibromyalgia | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
Hyperthyreosis | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
Hypothyreosis | 9 (8%) | 6 (16%) | 3 (6%) | 0.366 |
Malignancy | 3 (3%) | 0 (0%) | 5 (11%) | 0.051 |
Migraine | 10 (11%) | 1 (3%) | 0 (0%) | 0.023 |
Obstructive sleep apnoea | 7 (8%) | 0 (0%) | 0 (0%) | 0.041 |
Peripheral arterial occlusive disease | 1 (1%) | 0 (0%) | 0 (0%) | 0.999 |
Restless legs syndrome | 2 (2%) | 0 (0%) | 0 (0%) | 0.725 |
Rheumatoid arthritis | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
Spinal disc herniation | 0 (0%) | 0 (0%) | 1 (2%) | 0.485 |
